INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 05/12/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 05/11/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ImmunityBio Inc. (IBRX) InvestigationBusiness Wire • 05/11/23
ImmunityBio in dramatic selloff as FDA puts bladder cancer treatment on holdProactive Investors • 05/11/23
ImmunityBio stock loses more than half its value after disclosing FDA can't approve the BLA for its cancer treatment in its present formMarket Watch • 05/11/23
National Multicenter Trial Opens to Study ImmunityBio's Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch SyndromeBusiness Wire • 04/25/23
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services UniversityBusiness Wire • 04/25/23
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG' at ASCO GUBusiness Wire • 02/16/23
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional InvestorsBusiness Wire • 02/15/23
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to RegistrationBusiness Wire • 01/19/23
ImmunityBio Announces $157 Million Financing From Nant and Institutional InvestorBusiness Wire • 12/12/22
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare ConferenceBusiness Wire • 11/17/22